• Molina Healthcare reported first-quarter 2026 results on April 22, 2026, with revenue of US$10.80 billion versus US$11.15 billion a year earlier, and net income of US$14.0 million compared with US$298.0 million, while also issuing full-year 2026 GAAP earnings guidance of at least US$1.90 per diluted share.
• Behind the headline earnings drop, the company still delivered adjusted EPS above market expectations and reaffirmed its full-year adjusted EPS outlook, highlighting the importance of medical cost control and product mix shifts amid pressures from Medicaid attrition and trimmed revenue guidance.
• Next, we’ll examine how reaffirmed earnings guidance despite lower revenue expectations could affect Molina Healthcare’s investment narrative and perceived earnings resilience.

Find 52 companies with promising cash flow potential yet trading below their fair value.

Molina Healthcare Investment Narrative Recap

To own Molina Healthcare, you need to believe its Medicaid focused model and tight medical cost control can support earnings even when revenue softens or membership slips. The latest quarter underlines that tension: GAAP earnings fell sharply, but adjusted EPS beat expectations and full year adjusted EPS guidance was reaffirmed, suggesting the near term earnings catalyst still hinges on execution in Medicaid and Medicare, while the biggest current risk remains policy and reimbursement pressure on government programs.

In that context, Molina’s decision to reaffirm guidance of at least US$5.00 in adjusted EPS on roughly US$42 billion of 2026 premium revenue is particularly relevant. It connects directly to the earnings resilience story investors are watching after the Q4 2025 shock and the Q1 2026 GAAP earnings drop, and it frames how much room there may be for the company to absorb Medicaid attrition, Marketplace adjustments, and higher medical costs without materially resetting its profit outlook.

Yet beneath the reaffirmed guidance, the increased Medicaid attrition and rising medical cost trend could still pose a challenge investors should be aware of...

Molina Healthcare's narrative projects $49.2 billion revenue and $516.5 million earnings by 2029. This requires 4.1% yearly revenue growth and a $44.5 million earnings increase from $472.0 million today.

Uncover how Molina Healthcare's forecasts yield a $149.76 fair value, a 16% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting Molina to reach about US$53.7 billion in revenue and US$1.5 billion in earnings by 2028, which is far more bullish than the baseline view and could look very different now that Q1 2026 GAAP earnings have fallen so sharply and Medicaid attrition is rising.

Explore 11 other fair value estimates on Molina Healthcare - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Molina Healthcare research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Molina Healthcare research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Molina Healthcare's overall financial health at a glance.

Want Some Alternatives?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 18 early-stage AI stocks could fund your retirement.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.